Pharmaceuticals, Biotechnology & Life Sciences

Vistagen Therapeutics (VTGN) faces steep short‑interest decline, $23 M market cap, and a March 2026 class‑action deadline—investors must act before potential payouts vanish.

Tonix Pharmaceuticals (TNXP) explores CNS drug breakthroughs for fibromyalgia & PTSD amid volatile biotech markets—learn its pipeline, financial outlook, and investor updates.

Hyperliquid Strategies Inc. thrives amid geopolitical turmoil, offering 24/7 crypto‑commodity liquidity that could boost investor returns.

Cronos Group’s Q4 earnings miss reveals forex‑driven earnings pressure, yet revenue beats and strategic moves—including a European acquisition and Cyprus gas project—signal growth potential.

BioMarin’s FDA approval expands PALYNZIQ to 12‑year‑old PKU patients, boosting sales and analyst targets to $104—key for investors watching earnings and growth prospects.

Discover how Anavex Life Sciences Corp is advancing precision genetic medicine for rare neurological disorders, with CEO insights and board expansion fueling innovation.

Moderna’s mCOMBRIAX gets EU approval as the first combined COVID‑flu mRNA shot, promising single‑dose protection and a new revenue stream for the company.

Johnson & Johnson’s latest oncology breakthrough, new CereGlide device launch, and legal challenges are reshaping its $584B health‑care strategy, boosting investor confidence.

Discover how Eli Lilly’s new diabetes‑obesity drug, expanded Olumiant approval, and AI‑powered LillyPod partnership are reshaping its competitive edge and investor appeal.

ORIC Pharmaceuticals, a Nasdaq‑listed cancer‑treatment biotech, shows strong growth potential despite negative earnings; investors eye its latest research and upcoming investor conferences for future value.